Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
US Army
Moodys
Boehringer Ingelheim
Merck
Harvard Business School
Federal Trade Commission
Citi
AstraZeneca

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022184

« Back to Dashboard

NDA 022184 describes LUMIGAN, which is a drug marketed by Allergan and is included in two NDAs. It is available from two suppliers. There are twelve patents protecting this drug and two Paragraph IV challenges. Additional details are available on the LUMIGAN profile page.

The generic ingredient in LUMIGAN is bimatoprost. There are twelve drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.
Summary for 022184
Tradename:LUMIGAN
Applicant:Allergan
Ingredient:bimatoprost
Patents:12
Therapeutic Class:Ophthalmic Agents
Pharmacology for NDA: 022184
Ingredient-typeProstaglandins
Medical Subject Heading (MeSH) Categories for 022184
Suppliers and Packaging for NDA: 022184
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184 NDA Allergan, Inc. 0023-3205 N 0023-3205-02
LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184 NDA Allergan, Inc. 0023-3205 N 0023-3205-03

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION/DROPS;OPHTHALMICStrength0.01%
Approval Date:Aug 31, 2010TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Jun 13, 2027Product Flag?YSubstance Flag?YDelist Request?
Patent:➤ Sign UpPatent Expiration:Mar 16, 2025Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:Mar 16, 2025Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION

Expired US Patents for NDA 022184

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 ➤ Sign Up ➤ Sign Up
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 ➤ Sign Up ➤ Sign Up
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Colorcon
Mallinckrodt
Harvard Business School
Chubb
QuintilesIMS
Moodys
Julphar
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.